摘要
目的:探讨心脉隆注射液对冠心病(CHD)患者的疗效。方法:2016年9月~2017年9月我院收治的CHD患者108例被随机均分为常规治疗组和心脉隆组(在常规治疗组基础上加用心脉隆注射液),两组均治疗10d。观察比较两组治疗前后高敏C反应蛋白(hsCRP)、脑钠肽(BNP)、肿瘤坏死因子(TNF)-α水平、血液流变学、血脂水平,治疗效果以及不良反应发生率。结果:心脉隆组总有效率显著高于常规治疗组(94.44%比79.63%),P=0.022。与常规治疗组比较,心脉隆组治疗后hsCRP [(3.46±0.97)mg/L比(2.59±0.31)mg/L]、BNP[(357.38±52.19)pg/ml比(218.36±24.75)pg/ml]、TNF-α[(11.63±1.25)ng/L比(8.57±0.94)ng/L]、全血黏度高切[(5.21±0.59)mPa·s比(4.51±0.48)mPa·s]、全血黏度低切[(11.47±1.53)mPa·s比(9.73±1.04)mPa·s]、血浆黏度[PV,(1.29±0.14)mPa·s比(1.18±0.12)mPa·s]、红细胞压积[HCT,(44.85±4.52)%比(40.29±4.08)%]、LDL-C [(1.95±0.04)mmol/L比(1.53±0.03)mmol/L]、总胆固醇[(3.28±0.42)mmol/L比(2.31±0.35)mmol/L]和甘油三酯[(1.81±0.27)mmol/L比(1.36±0.17)mmol/L]水平均显著降低,HDL-C水平[(1.74±0.22)mmol/L比(1.87±0.21)mmol/L]显著升高,P均<0.01。心脉隆组不良反应发生率显著低于常规治疗组(3.70%比18.52%),P=0.014。结论:冠心病患者在常规药物治疗基础上联合应用心脉隆可显著提高疗效,改善炎症反应,降低血液流变学指标以及血脂水平,且无显著不良反应,安全性高,值得推广。
Objective:To explore therapeutic effect of Xinmailong injection on patients with coronary heart disease(CHD).Methods:A total of 108 CHD patients,who were treated in our hospital from Sep 2016 to Sep 2017,were randomly and equally divided into routine treatment group and Xinmailong group(received Xinamilong injection based on routine treatment group),both groups were treated for 10 d.Levels of high sensitive C reactive protein(hsCRP),brain natriuretic peptide(BNP),tumor necrosis factor(TNF)-α,hemorheological indexes,blood lipids before and after treatment,therapeutic effect and incidence of adverse reactions were observed and compared between two groups.Results:Total effective rate of Xinmailong group was significantly higher than that of routine treatment group(94.44%vs.79.63%),P=0.022.Compared with routine treatment group after treatment,there were significant reductions in levels of hsCRP[(3.46±0.97)mg/L vs.(2.59±0.31)mg/L],BNP [(357.38±52.19)pg/ml vs.(218.36±24.75)pg/ml],TNF-α[(11.63±1.25)ng/L vs.(8.57±0.94)ng/L],whole blood high shear viscosity[(5.21±0.59)mPa·s vs.(4.51±0.48)mPa·s],whole blood low shear viscosity[(11.47±1.53)mPa·s vs.(9.73±1.04)mPa·s],plasma viscosity[PV,(1.29±0.14)mPa·s vs.(1.18±0.12)mPa·s],hematocrit[HCT,(44.85±4.52)% vs.(40.29±4.08)%],LDL-C [(1.95±0.04)mmol/L vs.(1.53±0.03)mmol/L],total cholesterol[(3.28±0.42)mmol/L vs.(2.31±0.35)mmol/L]and triglyceride[(1.81±0.27)mmol/L vs.(1.36±0.17)mmol/L],and significant rise in HDL-C level[(1.74±0.22)mmol/L vs.(1.87±0.21)mmol/L]in Xinmailong group,P<0.01 all.Incidence rate of adverse reactions in Xinmailong group was significantly lower than that of routine treatment group(3.70% vs.18.52%),P=0.014.Conclusion:Application of Xinmailong injection based on routine medication can significantly improve therapeutic effect and inflammatory reactions,reduce hemorheological index and blood lipid levels in CHD patients.There is no significant adverse reactions and the safety is good,which is worth extending.
作者
郑婉
林燕仔
王敏
ZHENG Wan;LIN Yan-zi;WANG Min(Department of Cardiology,First Affiliated Hospital of Hainan Medical College,Haikou,Hainan,570102,China)
出处
《心血管康复医学杂志》
CAS
2020年第1期118-123,共6页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
冠心病
冠状血管
炎症
Coronary disease
Coronary vessels
Inflammation
